Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Dendritic cell-derived exosomes (Dex) are small extracellular vesicles secreted by viable dendritic cells. In the two phase-I trials that we conducted using the first generation of Dex (IFN-γ-free) in end-stage cancer, we reported that Dex exerted natural killer (NK) cell effector functions in patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Benjamin Besse, Mélinda Charrier, Valérie Lapierre, Eric Dansin, Olivier Lantz, David Planchard, Thierry Le Chevalier, Alain Livartoski, Fabrice Barlesi, Agnès Laplanche, Stéphanie Ploix, Nadège Vimond, Isabelle Peguillet, Clotilde Théry, Ludovic Lacroix, Inka Zoernig, Kavita Dhodapkar, Madhav Dhodapkar, Sophie Viaud, Jean-Charles Soria, Katrin S. Reiners, Elke Pogge von Strandmann, Frédéric Vély, Sylvie Rusakiewicz, Alexander Eggermont, Jonathan M. Pitt, Laurence Zitvogel, Nathalie Chaput
Format: Article
Language:English
Published: Taylor & Francis Group 2016-04-01
Series:OncoImmunology
Subjects:
cancer vaccine
exosomes
immunotherapy
NSCLC
NK cell
phase II trial
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2015.1071008
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2015.1071008

Similar Items